![Sample our Education journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5932/TOC-Subject-Sample-2021-Education.jpg"})
Abstract
The Alliance Scholar address briefly reviews nicotine, the biology of addiction, and the association of nicotine, depression, and the endocannabinoid system to tobacco dependence. Moreover, the latest management options for treating nicotine dependence are reviewed which include the Food and Drug Administration's (FDA) approved nicotine replacement therapies (i.e., nicotine polacrilex (2 mg and 4 mg), nicotine transdermal patch, the nicotine nasal spray, the nicotine oral inhaler, and the nicotine lozenge). In addition, the only non-nicotine smoking management option approved by the FDA is also discussed (i.e., bupropion SR, an anti-depressant). Finally, two investigational drugs (rimonabant and varenicline) currently being evaluated for treating nicotine dependence are briefly reviewed.